Drug:
Reaction: GENERAL PHYSICAL HEALTH DETERIORATION
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26519803 |
US |
60 | 2 |
Transient ischaemic attack, Diarrhoea, Hypertension, Aphasia, Fatigue, Dry skin, Dry mouth, Nasal dryness, General physical health deterioration, |
||||
LENVATINIB, LENVATINIB, |
||||
| 202 | 26519975 |
83 | 2 | |
General physical health deterioration, |
||||
RIOCIGUAT, RIOCIGUAT, |
||||
| 203 | 26520488 |
EU |
59 | |
Lymphoma, Richter^s syndrome, Testicular neoplasm, Submandibular gland enlargement, Dysphonia, Night sweats, Stress, General physical health deterioration, Dyspnoea exertional, Dyspnoea, Pain in extremity, Asthenia, Off label use, |
||||
RITUXIMAB, VENETOCLAX, PIRTOBRUTINIB, |
||||
| 204 | 26520511 |
CA |
78 | 1 |
Accidental death, Acute kidney injury, Acute respiratory failure, Altered state of consciousness, Asthenia, Delirium, Diarrhoea, Emphysema, Endotracheal intubation, Fall, Fungal oesophagitis, General physical health deterioration, Metabolic acidosis, Pancytopenia, Pneumocystis jirovecii pneumonia, Pulmonary function test decreased, Renal impairment, Septic shock, Toxicity to various agents, Ventricular tachycardia, Weaning failure, |
||||
METHOTREXATE, METHOTREXATE SODIUM, PANTOPRAZOLE, |
||||
| 205 | 26520705 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 206 | 26520928 |
GB |
||
General physical health deterioration, Cognitive disorder, |
||||
BREXUCABTAGENE AUTOLEUCEL, |
||||
| 207 | 26512249 |
US |
54 | 2 |
Back disorder, General physical health deterioration, |
||||
ABATACEPT, |
||||
| 208 | 26512454 |
CA |
68 | 2 |
Gastrointestinal hypermotility, Abnormal loss of weight, General physical health deterioration, Off label use, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, CHOLESTYRAMINE, DIMENHYDRINATE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, COLESEVELAM, |
||||
| 209 | 26512771 |
78 | ||
Condition aggravated, Inflammation, Pain, General physical health deterioration, Physical disability, Impaired quality of life, Mass, Dyspepsia, Stress, Abdominal pain upper, Adverse reaction, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, LEFLUNOMIDE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, ABATACEPT, ABATACEPT, ABATACEPT, |
||||
| 210 | 26512954 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 211 | 26513001 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 212 | 26513142 |
US |
1 | |
General physical health deterioration, Hallucination, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 213 | 26513429 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 214 | 26513486 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 215 | 26513632 |
US |
||
Illness, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 216 | 26513907 |
EU |
75 | 1 |
Dementia, Palliative care, General physical health deterioration, Heart rate increased, Respiratory rate increased, Pain, |
||||
FOSCARBIDOPA/FOSLEVODOPA, FOSCARBIDOPA/FOSLEVODOPA, |
||||
| 217 | 26513930 |
US |
2 | |
Pneumonia, General physical health deterioration, Chemotherapy, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 218 | 26514058 |
EU |
76 | 1 |
Death, Fluid intake reduced, Hypophagia, General physical health deterioration, Life expectancy shortened, |
||||
FOSCARBIDOPA/FOSLEVODOPA, ROPINIROLE, PANTOPRAZOLE, QUETIAPINE, |
||||
| 219 | 26514302 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 220 | 26514881 |
60 | 2 | |
Death, General physical health deterioration, |
||||
ABEMACICLIB, |
||||
| 221 | 26514947 |
US |
2 | |
Pain, General physical health deterioration, |
||||
SECUKINUMAB, |
||||
| 222 | 26515617 |
CA |
43 | 2 |
Abdominal discomfort, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Asthma, Blister, Breast cancer stage III, Condition aggravated, Contraindicated product administered, Decreased appetite, Depression, Diarrhoea, Discomfort, Drug hypersensitivity, Drug ineffective, Drug intolerance, Drug tolerance decreased, Duodenal ulcer perforation, Maternal exposure during pregnancy, Fatigue, Fibromyalgia, General physical health deterioration, Glossodynia, Hand deformity, Helicobacter infection, Hypersensitivity, Hepatic enzyme increased, Infusion related reaction, Hypoaesthesia, Joint swelling, Pain, Pemphigus, Pericarditis, Off label use, Product use issue, Rash, Rheumatoid factor positive, Swelling, Synovitis, Systemic lupus erythematosus, Treatment failure, Wound, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, |
||||
| 223 | 26515624 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 224 | 26515994 |
US |
2 | |
Rheumatoid arthritis, Laryngitis, General physical health deterioration, Osteoporosis, |
||||
| 225 | 26516358 |
US |
1 | |
General physical health deterioration, |
||||
NUSINERSEN, RISDIPLAM, |
||||
| 226 | 26516460 |
CA |
84 | 2 |
Cerebrovascular accident, General physical health deterioration, |
||||
PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, VEDOLIZUMAB, PREDNISONE, ZOLPIDEM TARTRATE, LEVOTHYROXINE SODIUM, ROSUVASTATIN, |
||||
| 227 | 26516658 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 228 | 26516679 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 229 | 26519109 |
36 | 2 | |
Micturition urgency, Pollakiuria, Urinary retention, General physical health deterioration, Mental impairment, |
||||
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE, BUPROPION, OXCARBAZEPINE, PANTOPRAZOLE, NARATRIPTAN, PEPPERMINT OIL, FREMANEZUMAB-VFRM, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, BENZOYL PEROXIDE, SENNOSIDES AND DOCUSATE SODIUM, SENNA-S, SENNOSIDES 8.6MG AND DOCUSATE SODIUM 50MG, DOCUSATE SODIUM AND SENNOSIDES, DOCUSATE SODIUM 50MG AND SENNOSIDES 8.6MG, SENNA AND DOCUSATE SODIUM TABLETS, 8.6 MG AND 50 MG, SENNOSIDES, DOCUSATE SODIUM, SENNOSIDES, SENNOSIDES 8.6 MG AND DOCUSATE SODIUM 50 MG, MAGNESIUM, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, CAMPHOR (SYNTHETIC), LEVOMENTHOL, AND CAPSICUM, CAMPHOR (SYNTHETIC) AND MENTHOL, UNSPECIFIED FORM, CAMPHOR (SYNTHETIC) AND MENTHOL, METHYL SALICYLATE AND MENTHOL, CAMPHOR (SYNTHETIC), MENTHOL, AND CAPSICUM, METHYL SALICYLATE, MENTHOL, UNSPECIFIED FORM, AND CAMPHOR (SYNTHETIC), METHYL SALICYLATE AND MENTHOL, UNSPECIFIED FORM, |
||||
| 230 | 26507800 |
US |
55 | 1 |
Atrial fibrillation, Upper-airway cough syndrome, Nasal congestion, Rhinorrhoea, Cough, Chest discomfort, Dyspnoea, Wheezing, General physical health deterioration, Breath sounds abnormal, Upper respiratory tract infection, Sinus disorder, |
||||
MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, MONTELUKAST, PREDNISONE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 231 | 26508001 |
CA |
80 | 1 |
Death, General physical health deterioration, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 232 | 26508138 |
EU |
2 | |
Tachycardia, Dyspnoea, General physical health deterioration, Pyrexia, |
||||
METHOTREXATE, METHOTREXATE SODIUM, LEFLUNOMIDE, RIBOCICLIB, |
||||
| 233 | 26508413 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 234 | 26508433 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 235 | 26508490 |
US |
2 | |
Langerhans^ cell histiocytosis, Neurodegenerative disorder, General physical health deterioration, Off label use, |
||||
PREDNISONE, METHOTREXATE, METHOTREXATE SODIUM, CYTARABINE, MELPHALAN HYDROCHLORIDE, MELPHALAN, |
||||
| 236 | 26508644 |
US |
56 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 237 | 26509044 |
VN |
2 | |
General physical health deterioration, |
||||
OSIMERTINIB, |
||||
| 238 | 26509112 |
EU |
54 | 1 |
Respiratory failure, Sepsis, Drug ineffective, General physical health deterioration, |
||||
FILGRASTIM, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 239 | 26509139 |
CA |
||
Autonomic nervous system imbalance, Abdominal discomfort, Hypotension, General physical health deterioration, Emotional distress, Muscle contractions involuntary, Fatigue, Asthenia, Presyncope, Hypertonia, Tremor, Dizziness, |
||||
LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, |
||||
| 240 | 26509349 |
US |
1 | |
Illness, Delusion, General physical health deterioration, Malaise, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 241 | 26509508 |
EU |
73 | 1 |
Pneumonia, Underdose, Contraindicated product administered, Hypokinesia, Device use error, Weight decreased, Nasopharyngitis, Decubitus ulcer, Secretion discharge, Akinesia, Dyskinesia, Asthenia, Weight decreased, Hyperkinesia, Psychomotor hyperactivity, Somnolence, Dysarthria, General physical health deterioration, Incorrect dose administered, Device issue, Psychomotor hyperactivity, |
||||
CLINDAMYCIN HYDROCHLORIDE, OXAZEPAM, OXYCODONE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BISOPROLOL FUMARATE, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, PREGABALIN, ROTIGOTINE, DARIFENACIN HYDROBROMIDE, PANTOPRAZOLE, MAGNESIUM, OXYCODONE, MIRTAZAPINE, AMANTADINE, SERTRALINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, SIMVASTATIN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, AMLODIPINE, CANDESARTAN, |
||||
| 242 | 26509991 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 243 | 26510052 |
VN |
1 | |
General physical health deterioration, |
||||
OSIMERTINIB, |
||||
| 244 | 26510092 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 245 | 26510341 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 246 | 26510457 |
VN |
2 | |
General physical health deterioration, |
||||
OSIMERTINIB, |
||||
| 247 | 26510576 |
EU |
85 | 2 |
Fall, Femur fracture, General physical health deterioration, Post procedural haematoma, Bedridden, Off label use, Anaemia, |
||||
BISOPROLOL FUMARATE, FUROSEMIDE, EMPAGLIFLOZIN, |
||||
| 248 | 26510756 |
EU |
74 | 1 |
Death, Asthenia, Thrombolysis, Ventricular dysfunction, General physical health deterioration, |
||||
AXITINIB, |
||||
| 249 | 26511031 |
EU |
23 | 2 |
Diarrhoea, Hyperaesthesia, General physical health deterioration, Product use issue, Product use issue, Off label use, |
||||
TRAMETINIB, TRAMETINIB, BINIMETINIB, BINIMETINIB, ENCORAFENIB, ENCORAFENIB, PEMBROLIZUMAB, PEMBROLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, LANSOPRAZOLE, LANSOPRAZOLE, GABAPENTIN, QUETIAPINE, PREDNISONE, PREDNISONE, OXAZEPAM, MORPHINE, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, |
||||
| 250 | 26511436 |
EU |
86 | 2 |
Immunotoxicity, General physical health deterioration, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, DOSTARLIMAB, |
||||
| 251 | 26511575 |
US |
1 | |
Skin cancer, Atrial fibrillation, Skin atrophy, Skin injury, Skin haemorrhage, Skin disorder, Osteoarthritis, Joint injury, Wound haemorrhage, General physical health deterioration, |
||||
RISANKIZUMAB-RZAA, |
||||
| 252 | 26511651 |
CO |
61 | 1 |
Death, General physical health deterioration, Prosopagnosia, Aphasia, |
||||
OSIMERTINIB, |
||||
| 253 | 26511687 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 254 | 26511791 |
CA |
40 | 2 |
Abdominal distension, Arthralgia, Arthropathy, Back injury, Blepharospasm, Blister, Breast cancer stage III, Bursitis, Coeliac disease, Condition aggravated, Confusional state, Contusion, Depression, Dizziness, Drug hypersensitivity, Dry mouth, Duodenal ulcer perforation, Dyspepsia, Dyspnoea, Epilepsy, Facet joint syndrome, Fall, Fatigue, Fibromyalgia, Finger deformity, Folliculitis, Gait inability, Gastrointestinal disorder, Gastrooesophageal reflux disease, General physical health deterioration, Glossodynia, Hand deformity, Headache, Helicobacter infection, Hypercholesterolaemia, Hypersensitivity, Hypertension, Hypoaesthesia, Impaired healing, Inflammation, Infusion related reaction, Injection site reaction, Injury, Insomnia, Irritable bowel syndrome, Joint range of motion decreased, Joint swelling, Lip dry, Liver injury, Lung disorder, Memory impairment, Migraine, Mobility decreased, Muscle injury, Muscle spasms, Muscular weakness, Musculoskeletal pain, Musculoskeletal stiffness, Nail disorder, Nasopharyngitis, Neck pain, Night sweats, Obesity, Onychomadesis, Onychomycosis, Osteoarthritis, Pain, Pain in extremity, Paraesthesia, Pemphigus, Pericarditis, Peripheral swelling, Peripheral venous disease, Psoriatic arthropathy, Rheumatic fever, Rheumatoid arthritis, Sleep disorder, Stomatitis, Swelling, Synovitis, Systemic lupus erythematosus, Taste disorder, Type 2 diabetes mellitus, Urticaria, Wheezing, Wound, Wound infection, Abdominal pain upper, Alopecia, Asthenia, Diarrhoea, Lower respiratory tract infection, Hepatitis, Drug-induced liver injury, Hypotension, Malaise, Nausea, Pneumonia, Rash, Vomiting, Abdominal discomfort, |
||||
AZATHIOPRINE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, CORTISONE ACETATE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ERENUMAB-AOOE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, ATOMOXETINE HYDROCHLORIDE, BOTULINUM TOXIN TYPE A, BUPRENORPHINE, CANDESARTAN, CELECOXIB, CELECOXIB, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, LAMOTRIGINE, LAMOTRIGINE, MEPOLIZUMAB, |
||||
| 255 | 26511798 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 256 | 26511799 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 257 | 26511822 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 258 | 26511885 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 259 | 26514025 |
78 | 1 | |
Hospice care, Pain, General physical health deterioration, |
||||
POMALIDOMIDE, |
||||
| 260 | 26502792 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 261 | 26503330 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 262 | 26503480 |
EU |
17 | 2 |
Colectomy, Anal ulcer, Large intestinal stenosis, Anal abscess, Anal stenosis, Abdominal pain, Diarrhoea, Illness, Proctalgia, General physical health deterioration, Proctalgia, Vaginal discharge, Weight decreased, Dyschezia, Defaecation urgency, Rectal discharge, Female genital tract fistula, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, INFLIXIMAB, USTEKINUMAB, AZATHIOPRINE, VEDOLIZUMAB, |
||||
| 263 | 26503491 |
CA |
44 | |
C-reactive protein, Dry mouth, Duodenal ulcer perforation, Facet joint syndrome, Fatigue, Fibromyalgia, General physical health deterioration, Glossodynia, Hand deformity, Hepatic enzyme increased, Hypersensitivity, Hypertension, Hypoaesthesia, Ill-defined disorder, Impaired healing, Inflammation, Infusion related reaction, Injury, Insomnia, Irritable bowel syndrome, Joint range of motion decreased, Joint swelling, Lip dry, Liver disorder, Malaise, Mobility decreased, Pruritus, Psoriatic arthropathy, Pyrexia, Rash, Rheumatic fever, Rheumatoid arthritis, Rheumatoid factor positive, Road traffic accident, Sciatica, Sleep disorder, Sleep disorder due to general medical condition, insomnia type, Stomatitis, Swelling, Swollen joint count increased, Synovitis, Systemic lupus erythematosus, Type 2 diabetes mellitus, Urticaria, Vomiting, Weight increased, Wheezing, Wound, Folliculitis, Helicobacter infection, Infection, Sinusitis, Intentional product use issue, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, INFLIXIMAB, INFLIXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, APREPITANT, LEFLUNOMIDE, CALCIUM CARBONATE, ANTACID, CELECOXIB, CELECOXIB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, HYDROCORTISONE, HYDROCORTISONE, CORTISONE ACETATE, CORTISONE ACETATE, CYANOCOBALAMIN, CYANOCOBALAMIN, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, ETANERCEPT, ETANERCEPT, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE, HYDROCORTISONE SODIUM SUCCINATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, LEFLUNOMIDE, PREGABALIN, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, ABATACEPT, ABATACEPT, APREMILAST, APREMILAST, OXYCODONE, OXYCODONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREGABALIN, PREGABALIN, INFLIXIMAB, INFLIXIMAB, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, GOLIMUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, USTEKINUMAB, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, TRIMETHOPRIM, PREDNISONE, PREDNISONE, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, TOFACITINIB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 264 | 26503598 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 265 | 26503621 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 266 | 26503906 |
US |
38 | 2 |
Drug dependence, Tooth loss, General physical health deterioration, Back pain, Restlessness, Pain, Insomnia, Drug ineffective, Dental caries, Emotional distress, Arthralgia, Pain in extremity, |
||||
BUPRENORPHINE, BUPRENORPHINE, |
||||
| 267 | 26504064 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 268 | 26504126 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 269 | 26504153 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 270 | 26504301 |
US |
1 | |
General physical health deterioration, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 271 | 26504384 |
US |
55 | 2 |
General physical health deterioration, |
||||
ABATACEPT, SARILUMAB, UPADACITINIB, |
||||
| 272 | 26504673 |
EU |
78 | 1 |
General physical health deterioration, Nausea, Vomiting, |
||||
OXALIPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, LEUCOVORIN CALCIUM, APREPITANT, FOSAPREPITANT DIMEGLUMINE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, METHYLPREDNISOLONE, |
||||
| 273 | 26504834 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 274 | 26505212 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 275 | 26505226 |
EU |
54 | 2 |
Multiple organ dysfunction syndrome, Plasma cell myeloma, Mobility decreased, General physical health deterioration, Pain, Haemoptysis, Febrile neutropenia, |
||||
MEROPENEM, CEFTRIAXONE, CEFTRIAXONE SODIUM, |
||||
| 276 | 26505248 |
US |
64 | 1 |
General physical health deterioration, Chronic kidney disease, Superinfection, Infected skin ulcer, Wound infection bacterial, Microscopic polyangiitis, |
||||
PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, RITUXIMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, COLCHICINE, |
||||
| 277 | 26505281 |
EU |
54 | 2 |
Multiple organ dysfunction syndrome, Plasma cell myeloma, Mobility decreased, General physical health deterioration, Pain, Haemoptysis, Febrile neutropenia, |
||||
CEFTRIAXONE, CEFTRIAXONE SODIUM, MEROPENEM, |
||||
| 278 | 26505374 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 279 | 26505783 |
HK |
55 | 2 |
General physical health deterioration, Haemorrhage intracranial, |
||||
LENVATINIB, PEMBROLIZUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 280 | 26505847 |
CA |
63 | 2 |
Vitamin B12 decreased, Back pain, Ear infection, Ear pain, Facet joint syndrome, Fall, General physical health deterioration, Hand fracture, Impetigo, Inappropriate schedule of product administration, Joint dislocation, Lower respiratory tract infection, Scoliosis, Tendon rupture, Tooth fracture, Upper limb fracture, Weight decreased, Weight increased, Drug hypersensitivity, |
||||
CYANOCOBALAMIN, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, CANNABIDIOL, CANNABIDIOL, LEVOTHYROXINE SODIUM, ERGOCALCIFEROL, |
||||
| 281 | 26505851 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 282 | 26506214 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 283 | 26506488 |
US |
2 | |
Cerebrovascular accident, General physical health deterioration, |
||||
INSULIN LISPRO, |
||||
| 284 | 26506872 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 285 | 26507032 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 286 | 26507114 |
US |
2 | |
Constipation, Metabolic disorder, Weight increased, Pain, Food craving, Blood pressure increased, Blood glucose increased, Anal incontinence, General physical health deterioration, Asthenia, Hyperphagia, Feeling abnormal, Dyspepsia, Gastric dilatation, Abdominal distension, Fluid retention, Drug ineffective, Product use issue, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, ESCITALOPRAM, |
||||
| 287 | 26507143 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 288 | 26507403 |
US |
69 | |
General physical health deterioration, Amyloidosis, Stress, Illness, Malaise, Asthenia, |
||||
| 289 | 26507603 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 290 | 26497953 |
TR |
1 | |
General physical health deterioration, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MELATONIN, |
||||
| 291 | 26498022 |
CA |
76 | |
Blood cholesterol increased, Decreased appetite, Fatigue, General physical health deterioration, Hepatic enzyme increased, Joint injury, Loss of consciousness, Pyrexia, Rheumatoid arthritis, Weight decreased, Constipation, Nervousness, Somnolence, Dizziness, Diarrhoea, Nausea, Drug effect less than expected, |
||||
ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, DESOXIMETASONE, PREDNISONE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 292 | 26498035 |
US |
||
General physical health deterioration, Wrong patient received product, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 293 | 26498060 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 294 | 26498087 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 295 | 26498573 |
US |
||
Bedridden, Feeling abnormal, General physical health deterioration, Dizziness, Cough, Dyspnoea, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, RIOCIGUAT, EMPAGLIFLOZIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, VITAMIN C, MIDODRINE HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE, DOCUSATE SODIUM, SENNOSIDES, DOCUSATE SODIUM AND SENNOSIDES, DOCUSATE SODIUM SENNOSIDES, ERGOCALCIFEROL, FUROSEMIDE, CYANOCOBALAMIN, METOLAZONE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, SPIRONOLACTONE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, OXYGEN, 0XYGEN, INSULIN LISPRO, MAGNESIUM, DORZOLAMIDE, FISH OIL, TIOTROPIUM BROMIDE AND OLODATEROL, |
||||
| 296 | 26498864 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 297 | 26498914 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 298 | 26499007 |
US |
||
General physical health deterioration, |
||||
ONABOTULINUMTOXINA, |
||||
| 299 | 26499008 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 300 | 26499292 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28